Drugs / Actemra IV Infusion
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04678739 | Aug 2020 → Jan 2021 | COVID-19, acute respiratory distress syndrome | M Abdur Rahim Medical College and Hospital | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Actemra IV Infusion | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04678739 ↗ |
| Route | Intravenous | “Tocilizumab I/V 8mg/Kg up to 800mg highest 12 hours apart” NCT04678739 ↗ |